

Triterpenoids and Sterones from the Stem Bark of *Ailanthus altissima*Xiao-Jiang Zhou,^{†,‡} Min Xu,[†] Xue-Song Li,^{†,‡} Yue-Hu Wang,[†] Ye Gao,[‡] Rui Cai,[‡] and Yong-Xian Cheng^{†,*}[†]State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, China. *E-mail: yxcheng@mail.kib.ac.cn[‡]College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China

Received July 28, 2010, Accepted November 2, 2010

One new tirucallane-type triterpenoid, alianthusaltinin A (**1**), one new C₂₉ sterone, alianthaltone A (**2**), and 12 known compounds have been isolated from the stem bark of *Ailanthus altissima*. The structures of new compounds were identified by means of spectroscopic methods. Compound **3** was isolated from natural sources for the first time, and compounds **4**, **5**, and **9** were isolated from this plant for the first time.

Key Words: *Ailanthus altissima* (Simaroubaceae), Tirucallane-type triterpenoids, Sterone, Alianthusaltinin A, Alianthaltone A

Introduction

Quassinoids, a group of bitter principles with various biological activities such as antimalarial, antitumor, antifeedant, anti-inflammatory, antiviral, and amoebicidal effects have attracted increasing interest in these years.¹⁻⁴ Simaroubaceae plants are known to be producers of quassinoids and thus have been extensively studied.⁴ *Ailanthus altissima* Swingle, a plant in the family of Simaroubaceae, is indigenous to China and has been introduced to Europe and the United States in the 18th century. The bark of this plant is used as an astringent in traditional Chinese medicine for the treatment of diarrhea, bleeding and tinea. As a source plant of quassinoids, *A. altissima* was also widely investigated. Previous reports revealed the presence of

quassinoids,⁵⁻⁷ alkaloids,⁸⁻¹⁰ and phenolic constituents,¹¹ and lipids in the plant.¹² As a part of our study on medicinal plants, we investigated the stem bark of this plant, and 14 compounds (Figure 1) including a new tirucallane-type triterpenoid (**1**) and a new C₂₉ sterone (**2**) were isolated. Herein, we describe the isolation and structure identification of the new compounds.

Results and Discussion

The molecular formula of compound **1** was determined to be C₃₀H₄₆O by its HRESIMS. The ¹³C NMR and DEPT spectra exhibited signals for seven methyl (one secondary and six tertiary), nine methylene (one olefinic), seven methine (three olefinic), and seven quaternary carbons (two olefinic, one carbonyl). These data in combination with two olefinic carbon signals (δ 117.8 CH, 145.9 qC) suggested that **1** is a tirucallane-type triterpenoid containing the functionalities of a $\Delta^{7,8}$ double bond and a carbonyl group at C-3. Comparing its NMR data with those of 23,26-dihydroxytirucalla-7,24-dien-3-one¹³ suggested that they had the same framework. The difference was at the side chain linked to C-17. ¹H, ¹H COSY cross peaks of H-21/H-20/H-22/H-23 (δ 5.62)/H-24 (δ 6.11) and HMBC correlations of H-27 (δ 1.83, 3H, s), H-23, H-24/C-25 (δ 142.2, qC); H-27/C-26 (δ 114.0, CH₂); H-24/C-26, C-27 (Figure 2) established the $\Delta^{23,24}$ and $\Delta^{25,26}$ double bonds. The geometry of $\Delta^{23,24}$ was assigned as *E*-form by the large $J_{H-23,H-24}$ value of 15.5 Hz. The relative configuration of **1** was determined by analysis of the NOESY spectrum, which showed the following correlations (Figure 3): H-2 β /H-28, H-19, H-9/H-18, H-30/H-17. Collectively, the structure of **1** was identified as (13 α ,14 β ,17 α ,20S,23*E*)-




Figure 1. The structures of compounds 1-14.





Figure 2. Important HMBC correlations for **1** and **2**.

Figure 3. Important NOESY correlations for **1**.Table 1. NMR data for **1**^a and **3**^a

No	1		3	
	¹³ C ^b	¹ H ^c	¹³ C ^b	¹ H ^c
1	38.5	1.98 (m) 1.45 (m)	38.4	1.98 (m) 1.45 (m)
2	34.9	2.74 (dt, 14.5, 5.5) 2.22 (m)	34.9	2.75 (dt, 14.5, 5.5) 2.24 (dt, 14.5, 3.5)
3	216.9		217.1	
4	48.0		47.8	
5	52.3	1.70 (m)	52.2	1.71 (t, 8.6)
6	24.3	2.07 (dt, 16.2, 3.3) 1.02 (m)	24.3	2.08 (ddd, 16.2, 8.6, 3.1) 1.71 (m)
7	117.8	5.29 (dd, 6.1, 3.3)	118.0	5.30 (dd, 6.1, 3.1)
8	145.9		145.6	
9	48.4	2.27 (m)	48.3	2.27 (t, 3.5)
10	34.9		34.9	
11	18.2	1.55 (m) 0.84 (m)	18.2	1.58 (m) 1.54 (m)
12	33.4	1.77 (m) 1.63 (m)	33.4	1.79 (m) 1.65 (m)
13	43.6		43.6	
14	51.5		51.2	
15	34.0	1.50 (m) 1.47 (m)	33.9	1.50 (m)
16	27.4	1.95 (m) 1.29 (m)	28.1	1.94 (m) 1.50 (m)
17	52.8	1.46 (m)	52.7	1.52 (m)
18	21.9	0.79 (s)	21.9	1.45 (s) 0.84 (s)
19	12.7	1.00 (s)	12.7	1.50 (m) 0.99 (s)
20	36.7	1.45 (m)	33.9	1.50 (m) 1.93 (m)
21	18.7	0.82 (d, 5.7)	19.2	0.97 (d, 6.4)
22	39.5	2.25 (m), 1.80 (m)	41.3	2.48 (dd, 3.1, 14.7), 2.03 (m)
23	129.5	5.62 (ddd, 15.5, 6.5, 3.3)	179.7	
24	134.0	6.11 (d, 15.5)	24.5	1.04 (s)
25	142.2		21.6	1.11 (s)
26	114.0	4.85 (s)	27.4	1.00 (s)
27	18.5	1.83 (s)		
28	24.5	1.02 (s)		
29	21.6	1.09 (s)		
30	27.3	1.00 (s)		

^aIn CD₃Cl; ^bmeasured at 100 MHz; ^cmeasured at 400 MHz.

Lanosta-7,23,25-trien-3-one, and given a name ailanthusal-tinin A.

Compound **2** had the molecular formula C₂₉H₄₆O₂ deduced from its HRESIMS. The NMR data of **2** were similar to those of compound **6**, except for the presence of the Δ^{6,7} double bond and a hydroxyl attached at C-20. ¹H, ¹H correlations of H-6 (δ

6.09)/H-7 (δ 6.11)/H-8 (δ 2.19)/H-9 (δ 1.18) and HMBC correlations of H-6, H-18 (δ 1.09)/C-5 (δ 163.9), H-6/C-8, H-7/C-8, C-9, C-14 suggested a Δ^{6,7} double bond (Figure 2). The chemical shift of C-20 (δ 75.2) and the molecular formula of **2** require a hydroxyl to be linked at C-20. The chemical shift for H₃-21 at δ 1.26 indicated the 20*S*-configuration (20*S*: δ 1.28; 20*R*: δ 1.13).^{14,15} The absolute configuration at C-24 of **2** remained unresolved. Take these data together, the structure of compound **2** was elucidated as (17*α*,20*S*)-20-Hydroxy-stigmasta-4,6-dien-3-one, namely ailanthalton A.

Known compounds were identified as (4,4,14-trimethyl-3-oxo-24-nor-5*α*,13*α*,14*β*,17*α*,20*S*-chol-7-en-23-oic acid) (**3**),¹⁶ hydroxydammarone I (**4**),¹⁷ ocotillone (**5**),¹⁸ stigmasta-4-ene-3-one (**6**),¹⁹ stigmasta-4,6,8(14),22-tetraen-3-one (**7**),²⁰ artelin (**8**),²¹ polystachyol (**9**),²² coniferyl alcohol (**10**), ferulic acid (**11**), 2,6-dimethoxyhydroquinone (**12**), antiarol (**13**), and 4-hydroxybenzaldehyde (**14**) by comparison with published literature data or direct identification by spectroscopic evidences. It was noted that compound **3** has been synthesized previously,¹⁶ however, it was isolated from natural sources for the first time. In addition, the NMR data of **3** were firstly assigned in this study (Table 1). Compounds **4**, **5**, and **9** were isolated from this plant for the first time. This study will help to get a deep insight into the chemical profiling of this medicinal plant.

Experimental Section

General Procedures. Optical rotations were recorded on a Horiba SEPA-300 polarimeter. UV spectra were measured on a Shimadzu UV-2401PC spectrophotometer. IR spectra were obtained on a Tensor 27 with KBr pellets. NMR spectra were recorded on a Bruker AM-400 or a DRX 500 or a Bruker Avance III-600 MHz spectrometer. ESI-MS and HRESIMS were determined with an API QSTAR Pulsar 1 spectrometer. Silica gel (200 - 300 mesh, 10 - 40 μm, Qingdao Marine Chemical Inc., Qingdao, China), RP-18 gel (40 - 63 μm, Daiso Co., Osaka, Japan), and Sephadex LH-20 (Amersham Biosciences, Uppsala, Sweden) were used for column chromatography.

Plant Material. The stem bark of *A. altissima* was purchased from Hunan Corporation of Materia Medica, Hunan Province, China, in July 2007, and authenticated by one of our authors (X. J. Zhou). A voucher specimen (CHYX-0084) was deposited at our laboratory in Kunming Institute of Botany.

Extraction and Isolation. The dried powdered stem bark of *A. altissima* (10 kg) was extracted with EtOH (2 × 30 L) to give an extract (720 g), which was suspended in water and partitioned by petroleum ether, EtOAc and *n*-BuOH (each 3 × 4 L), respectively. The petroleum ether extracts (150 g) was divided into fractions A-D by a silica gel column eluted with petroleum ether with increasing amounts of EtOAc. Fr. C (19 g) was divided into frs. C-1-C-4 by a MCI gel CHP 20P column eluted with a gradient aqueous MeOH. Compounds **4** (29 mg) and **5** (32 mg) crystals were readily obtained from fr. C-2 (1.6 g) and fr. C-3 (2.1 g), respectively. The mother liquor of fr. C-3 (1.2 g) was separated by silica gel column (CHCl₃/EtOAc, 100:2), Sephadex LH-20 (CHCl₃/MeOH, 6:4) and finally preparative thin layer chromatography (PTLC) (CHCl₃/EtOAc, 10:0.3) to give **8** (132 mg). Fr. C-4 (1.6 g) was submitted to vacuum liquid

Table 2. NMR data for **2**^a

No	2	
	¹³ C ^b	¹ H ^c
1	33.8	1.96 (ddd, 13.1, 5.3, 3.8) 1.67 (m)
2	33.8	2.64 (dt, 17.7, 5.3) 2.59 (dt, 17.7, 3.8)
3	199.7	
4	123.5	6.66 (s)
5	163.9	
6	127.9	6.09 (dd, 9.8, 2.3)
7	141.4	6.11 (dd, 9.8, 1.4)
8	37.0	2.19 (t-like, 10.6)
9	50.8	1.18 (m)
10	36.2	
11	20.5	1.61 (m), 1.45 (m)
12	40.1	2.11 (dt, 12.5, 4.0), 1.22 (m)
13	43.9	
14	53.7	1.21 (m)
15	24.1	1.24 (m), 1.07 (m)
16	23.2	1.18 (m), 1.08 (m)
17	57.3	1.21 (m)
18	13.5	0.92 (s)
19	16.2	1.09 (s)
20	75.2	
21	26.1	1.26 (s)
22	42.5	1.44 (m), 1.25 (m)
23	22.9	1.18 (m), 1.08 (m)
24	46.2	0.91 (m)
25	29.0	1.66 (m)
26	19.2	0.81 (d, 4.6)
27	19.5	0.81 (d, 4.6)
28	22.3	1.81 (m), 1.70 (m)
29	12.0	0.85 (d, 7.4)

^aIn CD₃Cl; ^bmeasured at 100 MHz; ^cmeasured at 400 MHz.

chromatography (VLC) on a silica gel column eluted with petroleum ether/EtOAc (98:3) to afford one fraction (530 mg) which was passed through a Sephadex LH-20 column (CHCl₃/MeOH, 6:4) to afford **1** (15 mg). Fr. B (8.5 g) was divided into B-1–B-3 over a silica gel column eluted with petroleum ether/EtOAc (10:0.2). Fr. B-2 (1.8 g) was submitted to a Sephadex LH-20 column (CHCl₃/MeOH, 6:4) and finally purified by PTLC (CHCl₃/EtOAc/iPrOH, 5:1:0.3) to yield **7** (10 mg). Fr. B-3 (5.5 g) was fractionated into B-3-1 and B-3-2 by a MCI gel CHP 20P column with 75% aqueous MeOH. Fr. B-3-1 (400 mg) was passed through Sephadex LH-20 (CHCl₃/MeOH, 6:4) followed by semi-preparative HPLC (Shimadzu, LC-10A HPLC system, Ultimate XB-C-18, 5 μm, 10 × 250 mm, i.d., 92% aqueous MeOH) to yield **2** (6 mg) and **3** (72 mg). Fr. B-3-2 (1 g) was chromatographed on a RP-18 column (88% aqueous MeOH) followed by PTLC (CHCl₃/EtOAc, 10:0.8) to give **6** (173 mg).

The *n*-BuOH soluble extracts (56 g) were subjected to a MCI gel CHP 20P column eluted with gradient aqueous MeOH to give fractions E–I. Fr. G (3.4 g) was separated over a silica gel column (petroleum ether/Me₂CO, 5:1) to afford fractions G-1 and G-2. Fr. G-2 (400 mg) was gel filtrated by Sephadex LH-20 (CHCl₃/MeOH, 6:4) and final semi-preparative HPLC (Shima-

dzu, LC-10A HPLC system, Ultimate XB-C-18, 5 μm, 10 × 250 mm, i.d., 67% aqueous MeOH) to yield **9** (9 mg) and **10** (15 mg). Fr. H (5.8 g) was divided into portions H1–H3 by VLC on silica gel with CHCl₃/EtOAc (6:1) as solvents. Fr. H-2 (800 mg) was repeatedly purified by silica gel column (petroleum ether/CHCl₃/EtOAc, 2:4:1) and final Sephadex LH-20 (CHCl₃/MeOH, 6:4) to afford **12** (18 mg), **13** (7 mg), and **14** (8 mg). Fr. H-3 (600 mg) was submitted to Sephadex LH-20 chromatography (MeOH) followed by PTLC (petroleum ether/CHCl₃/Me₂CO, 1:5:1) to give **11** (20 mg).

(13α,14β,17α,20S,23E)-Lanosta-7,23,25-trien-3-one (1): White solids; *R*_f = 0.65, silica gel GF₂₅₄, CHCl₃/Me₂CO (10:0.4); [α]_D¹⁸ -83.9 (c 0.1, MeOH:CHCl₃ 1:1); UV (MeOH): λ_{max} (log ε) = 230.6 (4.21); IR (KBr) ν_{max} 2952, 2933, 1710, 1630, 1457, 1370, 965 cm⁻¹; ¹H (400 MHz) and ¹³C NMR (100 MHz) data: see Table 1; ESIMS (positive) 423 [M + H]⁺, 445 [M + Na]⁺; HRESIMS (positive) 445.3447 ([M + Na]⁺, calcd. for C₃₀H₄₆O₂Na, 445.3446).

(17α,20S)-20-Hydroxy-stigmasta-4,6-dien-3-one (2): Colorless gums; *R*_f = 0.5, silica gel GF₂₅₄, CHCl₃/Me₂CO (10:0.5); [α]_D²⁴ -27.9 (c 0.22, MeOH); UV (MeOH): λ_{max} (log ε) = 285.8 (3.29). IR (KBr) ν_{max} 3444, 2957, 2933, 2869, 1660, 1616, 878, 804 cm⁻¹; ¹H (400 MHz) and ¹³C NMR (100 MHz) data see Table 2; ESIMS (negative) 425 [M - H]⁻, 461 [M + Cl]⁻; HRESIMS (positive) 449.3398 ([M + Na]⁺, calcd. for C₂₉H₄₆O₂Na, 449.3395).

Acknowledgments. This work was financially supported by a Project from Scientific Research Fund of Hunan Provincial Education Department (no.08c626), a Key Project for Drug Innovation (2008ZX09401-004) from the Ministry of Science and Technology of China, “Talent Scholarship for the Youth of Yunnan” (No. 2007PY01-48), and “Xi-Bu-Zhi-Guang” Project from the Chinese Academy of Sciences.

Supporting Information. The ¹H and ¹³C NMR spectra of compounds **1–3** are available on line.

References

- Yan, X. H.; Cheng, J.; Di, Y. T.; Fang, X.; Dong, J. H.; Sang, P.; Wang, Y. H.; He, H. P.; Zhang, Z. K.; Hao, X. J. *J. Agric. Food Chem.* **2010**, *58*, 1572.
- Beutler, J. A.; Kang, M. I.; Robert, F.; Clement, J. A.; Pelletier, J.; Colburn, N. H.; McKee, T. C.; Goncharova, E.; McMahon, J. B.; Henrich, C. J. *J. Nat. Prod.* **2009**, *72*, 503.
- Lidert, Z.; Wing, K.; Polonsky, J.; Imakura, Y.; Okano, M.; Tani, S.; Lin, Y. M.; Kiyokawa, H.; Lee, K. H. *J. Nat. Prod.* **1987**, *50*, 442.
- Guo, Z.; Vangapandu, S.; Sindelar, R. W.; Walker, L. A.; Sindelar, R. D. *Curr. Med. Chem.* **2005**, *12*, 173.
- Kubota, K.; Fukamiya, N.; Hamada, T.; Okano, M.; Tagahara, K.; Lee, K. H. *J. Nat. Prod.* **1996**, *59*, 683.
- Tamura, S.; Fukamiya, N.; Okano, M.; Koyama, J.; Koike, K. *Nat. Prod. Res.* **2006**, *20*, 1211.
- Tamura, S.; Fukamiya, N.; Okano, M.; Koyama, J.; Koike, K.; Tokuda, H.; Aoi, W.; Takayasu, J.; Kuchide, M.; Nishino, H. *Chem. Pharm. Bull.* **2003**, *51*, 385.
- Zhang, L. P.; Wang, J. Y.; Wang, W.; Cui, Y. X.; Cheng, D. L. *J. Asian Nat. Prod. Res.* **2007**, *9*, 253.
- Souleles, C.; Kokkalou, E. *Planta Med.* **1989**, *55*, 286.
- Crespi-Perellino, N.; Guicciardi, A.; Malyszko, G.; Arlandini, E.; Ballabio, M.; Minghetti, A. *J. Nat. Prod.* **1986**, *49*, 1010.

11. Hwang, S. W.; Lee, J. R.; Lee, J.; Kwon, H. S.; Yang, M. S.; Park, K. H. *Heterocycles* **2005**, *65*, 1963.
 12. Feo, V. D.; Martino, L. D.; Quaranta, E.; Pizza, C. *J. Agric. Food Chem.* **2003**, *51*, 1177.
 13. Luo, X. D.; Wu, S. H.; Ma, Y. B.; Wu, D. G. *Phytochemistry* **2000**, *54*, 801.
 14. Nes, W. R.; Varkey, E.; Crump, D. R.; Gut, M. *J. Org. Chem.* **1976**, *41*, 3429.
 15. Mijares, A.; Cargill, D. I.; Glasel, J. A.; Lieberman, S. *J. Org. Chem.* **1967**, *32*, 810.
 16. Breen, G. J. W.; Ritchie, E.; Sidwell, W. T. L.; Taylor, W. C. *Aust. J. Chem.* **1966**, *19*, 455.
 17. Poejlans, B. L.; Cart, B. K.; Francis, T. A.; Hylandh, L. J.; Allaudeen, S.; Troupe, N. *J. Nat. Prod.* **1987**, *50*, 706.
 18. Seger, C.; Pointinger, S.; Greger, H.; Hofer, O. *Tetrahedron Lett.* **2008**, *49*, 4313.
 19. Georgesa, P.; Sylvestrea, M.; Ruegger, H.; Bourgeoisa, P. *Steroids* **2006**, *71*, 647.
 20. Kobayashi, M.; Krishna, M. M.; Ishida, K.; Anjaneyulu, V. *Chem. Pharm. Bull.* **1992**, *40*, 72.
 21. Brown, D.; Asplund, R. O.; McMahon, V. A. *Phytochemistry* **1975**, *114*, 1083.
 22. Sadhu, S. K.; Phattanawasin, P.; Choudhuri, M. S. K.; Ohtsuki, T. M.; Ishibashi, M. *J. Nat. Med.* **2006**, *60*, 258.
-